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Abstract 
 
Spinal cord injury (SCI) is a leading cause of disability among young adults.  SCI is the 
result of trauma to the spinal cord, and most commonly occurs due to motor vehicle accidents.  
Treatment options for SCIs are limited and often have very serious consequences.  The 
recruitment and activation of innate immune cells at the site of injury affects recovery.  
Macrophages with a pro-inflammatory phenotype (M1) persist at the site of injury and are known 
to cause further damage.  These macrophages are important for the removal of debris and 
damaged tissue and the further recruitment of peripheral immune cells to the site of injury. 
Conversely, macrophages with a regenerative, anti-inflammatory phenotype (M2) are only 
transiently located at the site of SCI.  miRNAs are important regulators of inflammation in 
autoimmune and inflammatory disorders. miRNA are small, non-coding RNAs, approximately 
19-24 nucleotides in length, which regulate gene expression at the transcriptional level.  miRNA 
can bind messenger RNA (mRNA) through base pairing and induce the degradation of mRNA or 
inhibit its translation. Therefore, we hypothesized that miRNA play a key role in the M1 vs M2 
macrophage differentiation process. To identify miRNA involved in this process, the relative 
expression of several miRNA involved in inflammatory responses was analyzed in vitro in bone 
marrow derived macrophages (BMDM) undergoing differentiation into M1 versus M2 
phenotypes.  We found significantly higher expression levels of one miRNA in particular, miR-
155, in BMDM undergoing M1 differentiation, as compared to BMDM undergoing M2 
differentiation.  miR-155 knockout (KO) macrophages were unable to efficiently up-regulate 
inducible nitric oxide synthase (iNOS), a characteristic marker of M1 macrophages, as well as  
the inflammatory cytokine TNF-α.  Furthermore, the expression of arginase-1 (Arg1), a 
prototypical M2 marker, was stable or increased in miR-155 KO macrophages.  These results 
support the concept that miR-155 plays an important role in the differentiation of macrophages 
into the M1 phenotype and help lay a framework for understanding the mechanism(s) by which 
miRNA influence macrophage differentiation and inflammation after SCI. 
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Abbreviations 
 
Arg-1 Arginase-1 
AP-1 Activation Protein-1 
BBB Blood Brain Barrier 
BMDM Bone Marrow-Derived Macrophages 
CD Cluster of Differentiation  
CNS Central Nervous System 
CSPG Chondrotin Sulfate Proteoglycan 
DAMPs Danger-Associated Molecular Patterns 
FC Fold Change 
HMGB1 High Mobility Group Box-1 
IFN Interferon 
IL Interleukin 
iNOS Inducible Nitric Oxide Synthase 
IRAK-1 IL-1 Receptor Associate Kinase-1 
IRF Interferon Response Factor 
JAK Janus Kinase 
KO Knock-out 
LPS LipoPolySaccharide 
M&M Materials and Methods 
M0 Undifferentiated macrophages 
M1 Classically activated macrophages 
M2 Alternatively activated macrophages 
MAG Myelin Associated Glycoprotein 
MHCII Major Histocompatibility Complex Class II 
miRNA MicroRNA 
MMPs Matrix MetalloProteinases 
NF-κB Nuclear Factor – Kappa B 
NO Nitric Oxide 
PAMPs Pathogen-Associated Molecular Patterns 
Pre-miRNA Precursor miRNA 
Pri-miRNA Primary miRNA 
PRRs Pattern Recognition Receptors 
RISC RNA-Induced Silencing Complex 
SCI Spinal Cord Injury 
SOCS Suppressor of Cytokine Signaling 
STAT Signal Transducer and Activator of Transcription 
TGFβ Transforming Growth Factor beta 
TLR Toll-Like Receptors 
TNFα Tumor Necrosis Factor alpha 
UTR UnTranslated Region 
VEGF Vascular Endothelial Growth Factor 
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I   Background 
1.1 - Introduction 
 Spinal cord injury (SCI) is damage of the spinal cord that results from trauma as opposed 
to disease [1].  Although patients who survive the first 24 hours post-injury generally have a 
good survival rate, SCI has severe long-term consequences.  Depending on the location and 
severity of trauma, paraplegia (paralysis of two limbs) and quadriplegia (paralysis of four limbs) 
are common outcomes of SCI.  There are few treatment options, and functional recovery of 
patients is limited due the failure of the body to regenerate the central nervous system (CNS).  
Since damage resulting from SCI is exacerbated by the immune system’s inflammatory response 
to tissue injury, important efforts are being made to understand how this process occurs and 
identify new therapeutic targets [2].  In an effort to uncover possible molecular targets for 
therapy, this study examines the mechanisms by which a specific type of innate immune cell, the 
macrophage, differentiates into either a pro-inflammatory phenotype that contributes to damage 
(M1 phenotype) or an anti-inflammatory phenotype with pro-regenerative activity (M2 
phenotype).  
 
1.2 - Epidemiology 
SCI is estimated to affect approximately 270,000 people in the United States, with an 
estimated 12,000 new cases annually [1].  Since 2005, approximately 39.2% of SCIs have 
occurred as a result of automotive accidents, while accidental falls and violent assaults have 
accounted for the remaining 28.3% and 14.6%, respectively [1].  The average age of SCI patients 
is 42.6 years with a predominance of SCI occurring in males at 81.8%.  Disparities in the 
incidence of SCI based on race/ethnicity have also been noted, with 67% of SCIs occurring in 
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Caucasians, 24.4% in African Americans, 7.9% in Hispanics, 0.8% in Native Americans and 
2.1% in Asians [1]. 
 SCI presents a significant personal and societal financial burden. A high cervical injury 
resulting in quadriplegia has a first year cost of $1,044,197 and a lifetime cost of $4,633,137 [1]. 
The lifetime cost of treatment for a patient suffering from a lower SCI resulting in paraplegia is 
$2,265,584 after an initial first year cost of $508,904 [1].  Furthermore, the life expectancy of 
patients suffering from SCI is significantly diminished.  Historically, the leading cause of 
mortality among patients surviving SCI was renal failure; however, advances in urology have 
significantly reduced renal complications making pneumonia and septicemia the current leading 
causes of mortality among SCI patients [1].  While there has been an overall improvement in the 
mortality rate following SCI, there has been little improvement in overall functional recovery. 
 
1.3 - Current SCI Therapies 
 Treatment options for acute SCI have advanced minimally over the last 20 years.  The 
primary treatment option is high dose methylprednisolone sodium succinate bolus (30mg/kg) 
administered intravenously within the first 8 hours post-injury followed by continuous infusion 
for 24 hours (5.4/mg/kg/hour) [3].  Methylprednisolone, a synthetic glucocorticoid, has been 
shown in some studies to improve the neurologic function and recovery of patients after SCI 
versus patients receiving placebo [3].  This improved recovery includes improved motor function 
and improved sensation.  Other studies have shown similar results, though the improvements 
observed were not always considered statistically significant and one study showed no 
improvement in motor recovery [2-3].  Studies that extended the continuous methylprednisolone 
infusion from 24 hours to 48 hours initially demonstrated that patients achieved a greater level of 
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functional motor recovery; however these results were not considered statistically significant 
after follow-up at 6 months and 1 year.  Furthermore, the increased duration (48 hour) of 
methylprednisolone contributed to an increased rate of infection and sepsis, though no overall 
increase in the rate of mortality [2-3].  Thus, the immunosuppressive nature of 
methylprednisolone and other glucocorticoids increases the risk of infection and sepsis with 
increasing duration of use, which has limited their use as means of recovery for an extended 
period of time in SCI. 
While methylprednisolone acts as an immunosuppressive and anti-inflammatory agent 
post-SCI, its exact mechanism is not yet fully understood.  Methylprednisolone can cross the 
plasma membrane of affected cells relatively easily due to its characteristic hydrophobicity.  
Once inside the cell, it is believed that methylprednisolone binds a glucocorticoid receptor, 
which then migrates into the nucleus and prevents the generation of pro-inflammatory 
transcription factors such as nuclear factor-kappa B (NF-κB), activation protein-1 (AP-1) and 
interferon response factor (IRF) family transcription factors [3].  The rationale for treatment is 
that inhibiting the factors that stimulate cytokine and chemokine production at the site of SCI 
may be able to reduce secondary tissue damage and peripheral immune cell chemotaxis. 
While methylprednisolone is the predominant post-SCI therapy, there have been several 
recently developed alternatives that are currently under investigation.  Riluzole, an FDA-
approved treatment for amytrophic lateral sclerosis, is currently undergoing several pre-clinical 
studies identifying its potential effect on SCI recovery [2].  Riluzole acts as a voltage-sensitive 
receptor antagonist and also inhibits pre-synaptic calcium-dependent glutamate release. In rat 
models, studies have reported improved locomotive scores such as the Basso Beattie Bresnahan 
locomotive score, greater myelin sparing, and overall smaller lesions [2,4].  Cethrin, a Rho-
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antagonist that has recently entered clinical trials in humans, has been reported to improve 
functional recovery and reduce spinal cord lesion after direct application to the dura in mouse 
and rat models [2,5].  RhoA protein is a calcium-dependent GTPase central to the Rho/ROCK 
pathway, which inhibits the formation of growth cones on neurons - RhoA inhibition is expected 
to encourage nerve regeneration [2].  Preliminary analysis of phase I/II open-label trials in 
humans showed high levels of inter-patient variability.  Therefore, establishing efficacy will 
require a larger study population [2,5].  Finally, another treatment option currently being 
investigated for SCI is based on surgical decompression of the spinal cord immediately after 
injury.  However this strategy remains controversial.  Surgical decompression involves the 
surgical removal of sections of vertebrae at the site of injury as a method of relieving pressure 
[2].  Pre-clinical studies in animal models have yielded promising results of recovery post-SCI 
when decompression was performed within 24 hours post-injury [2,6].  Studies in animal models 
also noted that earlier decompression generally yielded improved recovery.  However, clinical 
studies of surgical decompression in humans have produced mixed results, further dividing the 
scientific community on its efficacy [2,6].  Additional studies will need to be completed before 
its effectiveness can be ascertained.  Overall, the limited number and effectiveness of SCI 
treatments combined with the severe and costly long-term consequences of this condition justify 
the need to identify new therapeutic targets for intervention. One of the current areas of 
investigation focuses on understanding the positive and negative effects of immune responses to 
SCI with the goal of identifying novel therapeutic targets. 
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1.4 - Immune Response to SCI 
SCI occurs over two major phases.  If the person survives the primary injury caused by 
direct trauma, then they must deal with the secondary injury caused by the ensuing immune 
response to tissue damage [7].  The primary SCI consists of the physical trauma to the spinal 
cord and the resulting direct tissue damage.  This includes the fracturing of vertebrae, severing of 
neurons and shearing of blood vessels [8].  This phase is accompanied by hemorrhaging, myelin 
destruction, and cell death. As a consequence of the initial injury, various cellular components 
that act as danger signals are released from damaged/dying cells [8]. These danger signals, called 
danger-associated molecular patterns (DAMPs), can include a wide variety of endogenous 
ligands.  DAMPs at the site of SCI include high mobility group box-1 (HMGB1), extracellular 
mRNA and ATP, hyaluronic acid, heat shock protein (HSP), fibronectin and oxidized lipids [8-
11].  CNS resident cells respond to these danger signals and initiate innate inflammatory 
responses which result in secondary injury. 
Microglia, the resident immune cells of the CNS, are capable of responding to DAMPs 
released at the site of SCI through pattern recognition receptors (PRRs).  PRRs recognize a 
variety of structural motifs that are conserved among pathogens, but similarly respond to 
DAMPs as a signal of cellular distress.  Microglia are known to express a variety of PRRs, 
including toll-like receptors (TLRs), NOD-like receptors, RIG-like receptors, scavenger 
receptors and C-type lectin receptors [8].  Other cells resident to the CNS, including neurons, 
astrocytes, and oligodendrocytes, are also known to express TLRs [8-11].  Activation of TLRs, 
particularly TLR-2 and TLR-4, can lead to either the MyD88 or TIR-domain-containing adapter-
inducing interferon-β (TRIF) signaling pathways which culminate in the activation of pro-
inflammatory transcription factors that mediate innate host defense mechanisms, including NF-
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κB, AP-1, and IRF [12-13].  NF-κB and AP-1 are responsible for the activation of genes 
associated with acute inflammation and stimulation of adaptive immunity, including the 
production of inflammatory cytokines IL-6, IL-8, IL-12, TNF-α, and IL-1β [14].  While this TLR 
stimulation has been reported to contribute to secondary tissue damage in SCI, deficiencies in 
either TLR2 or TLR4 signaling also result in exacerbated pathology and diminished functional 
recovery [15].  IRFs are predominantly responsible for the activation of the antiviral Type I 
interferons (IFN-α and IFN-β), though their role is not well-defined in the context of SCI.  
Microglia and oligodendrocytes produce monocyte chemotactic protein-1 (MCP-1), macrophage 
inflammatory protein-1α (MIP-1α), and stromal-derived factor (SDF) which contribute to the 
chemotaxis of macrophages from the periphery [16]. Furthermore, these macrophages then 
obtain entry to the CNS as a result of matrix metalloproteinases (MMPs) and vascular 
endothelial growth factor (VEGF) secreted by microglia, which aid in the permeabilization of the 
blood-brain barrier (BBB) [17]. 
 The first responders from the periphery are phagocytes involved in clearing myelin and 
cell debris.  After permeabilization of the BBB, peripheral monocytes infiltrate the CNS 
approximately 3 days post-injury [18].  Monocytes respond to the cytokines/chemokines secreted 
by microglia and cells of the CNS and localize to the site of SCI and differentiate into 
macrophages [20].  Neutrophils also infiltrate the site of SCI and phagocytose myelin, but any 
additional functions in the context of SCI are less well understood [18].  Macrophages 
phagocytose myelin and cell debris and release a variety of factors (described in section 1.5) 
which both enhance inflammation and degeneration. All of these phagocytes contribute to 
Wallerian degeneration - the extended axonal degeneration that occurs in the axon distal to the 
transection site.  Since neuronal regeneration in the CNS is relatively slow and often incomplete 
8  
when compared to the peripheral nervous system, neuronal degeneration in the CNS generally 
results in long-lasting if not permanent damage and is a main cause of impaired functional 
recovery in SCI [19-20].  
  
1.5– Macrophages in SCI  
Regardless of species or type of injury, intraspinal macrophage accumulation is a 
prominent and persistent component of experimental and clinical SCI [21-23]. The role of 
macrophages in SCI has been a topic of debate for many years.  Evidence elucidating their role 
in SCI was often contradictory among studies.  Initial research indicated that the presence of 
macrophages in early SCI was deleterious and exacerbated the injury [20].  However, studies 
which further investigated the effects of macrophage ablation post-SCI noted a decreased 
recovery in function pointing to a beneficial role of macrophages [24].  The apparently 
contradictory effects of macrophages in SCI pointed to the possibility that there were two 
populations of macrophages, each with its own unique phenotype, acting at the site of injury [25-
26].  This observation paralleled in vitro studies showing that two different activated macrophage 
phenotypes can be generated by exposing macrophages to different stimuli [27].  Classically 
activated macrophages (M1) are generated in response to PRR stimulation in the presence of 
IFN-γ, while alternatively activated macrophages (M2) are generated in response to the anti-
inflammatory cytokine, IL-4 [28].  SCI studies have since shown that M1 macrophages, which 
cause neurotoxicity and hamper neuroregeneration, persist in SCI lesions for several weeks post-
injury [27]. In contrast, M2 macrophages, which support axon growth and are non-neurotoxic, 
occupy the lesion site for only a few days post-injury [27].  This progressive “loss” of M2 
macrophages is thought to be due to the conversion of newly activated microglia and infiltrating 
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monocytes into M1 macrophages as they respond to pro-inflammatory signaling in the acute SCI 
environment. Therefore, therapeutic strategies that suppress M1 and enhance M2 macrophages 
after SCI are actively sought. 
Macrophages activated classically are distinguished from alternatively activated 
macrophages by specific surface markers characteristic of each phenotype.  The hallmark 
indicator of classically activated macrophages is the increased expression of Nos2, the gene 
encoding the enzyme inducible nitric oxide synthase (iNOS).  iNOS catalyzes the oxidation of L-
arginine into L-citrulline, resulting in the formation of nitric oxide (NO) [28-30].  The 
recognition of pathogen associated molecular patterns (PAMPs) by macrophages initiates a 
protective pro-inflammatory response, causing the release of NO intended to damage invading 
pathogens.  However, the release of NO by macrophages at the site of SCI can exacerbate the 
damage initially caused by the spinal cord trauma.  Another marker of M1 macrophages is the 
upregulation of major histocompatability complex II (MHCII).  After a macrophage 
phagocytoses a pathogen, the macrophage then processes the pathogen in phagolysozomes for 
presentation to CD4+ T-cells via MHCII [28].  In addition, classically activated macrophages up-
regulate the expression of CD86, a costimulatory molecule required for the activation of CD4+ 
T-cells during antigen presentation.  The combined increase in expression of MHCII and CD86 
in macrophages bridges the innate immune response with the adaptive immune response.  
Classically activated macrophages have also been reported to up-regulate the immunoglobulin 
receptors FcγRIII (CD16) and FcγRII (CD32) [28-29].  Neurons exposed to media from M1 
macrophages in vitro demonstrate shorter neurite growth and decreased survival [27]. 
In contrast, when macrophages respond to anti-inflammatory cytokines such as IL-4 and 
IL-13 they differentiate into M2 macrophages.  M2 macrophages are characterized by the 
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expression of Arg-1 [16-17].  The specific function of Arg-1 has not been conclusively 
established, but its expression appears to be inversely correlated with the expression of Nos2.  
M2 macrophages also upregulate the expression of the mannose receptor (CD206) and YM1, a 
heparin-binding lectin [16-17,27,30].  The scavenger receptors CD204 and CD163 have also 
been associated with the M2 macrophage phenotype, targeting low-density lipoproteins (LDLs) 
and the hemoglobin-haptoglobin complex, respectively [16-17,27,30].  In agreement with the 
above described release of damaging soluble factors, neurons exposed to media from M2 
macrophages in vitro exhibit longer neurite growth and sustained survivability [27]. 
Based on the contradicting results described in the first paragraph of this section, it has 
been hypothesized that macrophages which arrive at the site of SCI can differentiate into 
macrophages along a spectrum of phenotypes between two extremes.  One of these extremes is 
the pro-inflammatory, "M1" macrophage that would arise from exposure to the DAMPs released 
at the site of injury [28]. Classically activated macrophages respond with the release pro-
inflammatory cytokines (TNF-α, IL-1β, IL-6) and reactive oxygen species such as the superoxide 
anion (O2-), hydrogen peroxide (H2O2), and the hydroxyl radical (HO·) [28,30].  In addition, M1 
macrophages produce substantial quantities of cyclooxygenase-2 (COX2), which is 
enzymatically responsible for the conversion of arachidonic acid into lipid mediators of 
inflammation called prostanoids (including prostaglandins and thromboxanes) [17].  These 
molecules further contribute to the chemotaxis of inflammatory cells, increase vascular 
permeability, and contribute to pyrogenesis [17].  Further, M1 macrophages can also be 
detrimental to SCI recovery through the release of neuronal growth inhibitors, including Nogo, 
myelin associated glycoprotein (MAG), and condroitin sulfate proteoglycan (CSPG).  The 
localized interaction of these inhibitory molecules with microglia and astrocytes contribute to the 
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formation of a glial scar around the site of SCI [29].  While the purpose of the glial scar is to 
isolate the primary SCI from the uninjured CNS and prevent further damage, the glial scar also 
constitutes a physical barrier which prevents robust axonal growth and recovery [29].  Since the 
DAMPs that induce M1 macrophages continue to be present at the site of injury, classically 
activated macrophages remain at the site of SCI for an extended period of time contributing to 
secondary SCI [27]. 
 When macrophages are alternatively activated into anti-inflammatory "M2" macrophages 
in response to anti-inflammatory cytokines, including IL-4 and IL-13, they release anti-
inflammatory cytokines such as IL-10, TGF-β, and IL-1Rα as an immunoregulatory mechanism 
to moderate inflammatory responses.  The cytokine IL-10 acts as inhibitor of M1 macrophages 
by inhibiting the production of IL-12 and down-regulating the expression of MHCII and 
costimulatory molecules [32].  Additionally, M2 macrophages secrete TGF-β1, one of three 
closely related cytokines (TGF-β1, TGF-β2, TGF-β3) [17].  The production of TGF-β1 by 
alternatively activated macrophages further suppresses the activation of M1 macrophages, thus 
limiting the ability of M1 macrophages to promote inflammation.  In contrast to the pro-
inflammatory lipid mediators produced by M1 macrophages, M2 macrophages produce anti-
inflammatory lipid mediators including lipoxins, resolvins, and protectins [17,26].  Alternatively 
activated macrophages also release regenerative mediators which contribute to their role in 
matrix remodeling and tissue repair.  VEGF and platelet derived growth factor (PDGF) are both 
secreted by M2 macrophages to promote angiogenesis [17].  It is important to note that these 
alternatively activated macrophages exist as a much smaller population in comparison to 
classically activated macrophages at the site of SCI, and only transiently remain at the site of 
injury after the first two weeks post-injury [27].  One of the long-term goals of these studies is to 
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try to shift the balance of macrophages at the site of SCI from overwhelmingly M1 to M2 in an 
attempt to reduce inflammation and increase regeneration. 
  
1.6 –miRNA 
 miRNA are small, non-coding RNA approximately 19-24 nucleotides in length, that 
regulate gene expression at the post-transcriptional level [36].  miRNA were first described in 
Caenorhabditis elegans by Victor Ambros at Dartmouth College in the early 1990s [37].  
miRNA bind the 3’ UTR of their complementary target mRNA and either induce the degradation 
of the mRNA or prevent the mRNA from being translated [36].  The role miRNA play in both 
healthy host function and disease is a booming field of study.  Currently it is estimated that there 
are more than 2000 miRNA present in humans alone, and that more than one-third of all mRNA 
are regulated by miRNA [39-40]. 
miRNA can be encoded within the introns of protein-coding genes and therefore co-
expressed with their “host” gene or be independently encoded and transcriptionally regulated 
[40].  The biogenesis of miRNA involves several steps that start in the nucleus (Fig. 1). RNA 
polymerase II first transcribes primary-miRNA (pri-miRNA) before undergoing two processing 
steps involved in miRNA maturation.  The first step of miRNA maturation involves the RNAse 
III enzyme Drosha in conjunction with its partner protein DGCR8.  In the nucleus, the 
Drosha/DGCR8 complex processes pri-miRNA into a 70-nucleotide precursor-miRNA (pre-
miRNA) containing a hairpin [36,38-41].  Nuclear channels specific for pre-miRNA (Exportin 
5/RanGTP) transport the molecules into the cytoplasm where they undergo the second step in 
miRNA maturation.  The RNAse, Dicer, cleaves the hairpin in pre-miRNA, forming a miRNA 
duplex [36,38-41].  One strand from the miRNA duplex is loaded into the RNA-induced 
13  
silencing complex (RISC) which binds the 3’ untranslated region (UTR) of target mRNA.  The 
subsequent translation of the target mRNA is either inhibited by the bound miRNA or the target 
mRNA is degraded by RNAses in the cytoplasm [36,38-41]. 
 
 
Figure 1. miRNA biogenesis pathway.  miRNA are encoded in the genome and transcribed by RNA 
polymerase II into primary miRNA (Pri-miRNA) which have a hairpin structure with overhangs. Pri-
miRNA is then transcribed and processed by the Drosha/DGCR8 complex, which removes the hairpin 
overhangs, into precursor miRNA (Pre-miRNA).  Pre-miRNA exit the nucleus via Exportin 5 and reach 
the cytoplasm, where they are processed into a miRNA duplex without overhangs by Dicer. The leading 
strand of the miRNA duplex is then  loaded onto the RNA-induced Silencing Complex (RISC) which 
then joins the miRNA with its target mRNA either inducing degradation or preventing translation. 
 
The role miRNA play in immune regulation and inflammatory conditions has been the 
subject of numerous studies.  Several key regulatory proteins of immune development and 
function have been shown to be direct targets of miRNA.  For example, TNF receptor-associated 
factor-6 (TRAF6) and IL-1 receptor-associated kinase-1 (IRAK-1), which are key components of 
the TLR4 signaling pathway, are confirmed targets of miR-146a [42].  It has been demonstrated 
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that miR-155 plays a vital role in establishing an adaptive immune response to Salmonella 
typhimurium [43].  Mice with deficient bic/miR-155 exhibit impaired B-cell and T-cell function, 
in addition to defective antigen presentation [44].  miR-155 is also reported to target the 
transcription factor PU.1 in B cells, which is important in both germinal center response and IgG 
class switching [40].  Dysregulation in miRNA expression has been linked to an assortment of 
autoimmune and inflammatory conditions, including systemic lupus erythematosus, multiple 
sclerosis, and rheumatoid arthritis [45-48].  This thesis explores the possibility that in addition to 
the roles mentioned above, miR-155 may be important for the shift between M1 and M2 
macrophage phenotypes in the spinal cord after injury. 
 
II   Materials and Methods 
2.1 – Mice 
Wild-type (WT) or miR-155 KO (B6.Cg-Mir155tm1.1Rsky/J) mice on the C57Bl6/J 
background originally obtained from Jackson laboratories and kept in specific pathogen-free 
conditions were used in these studies. All animal experiment procedures were approved under 
Ohio State University’s IACUC protocol # 2009A0036-R1. 
 
2.2 –Cell Culture 
To generate bone marrow-derived macrophages (BMDM), the bone marrow cells from 
femurs and tibias from mice were harvested and cultured as previously described [13].  Briefly, 
isolated cells were incubated in Dulbecco’s Modified Eagle Media (DMEM) supplemented with 
10% bovine serum albumin, 1% penicillin/streptomycin, 1% glutamine, and 20% L929 
supernatant (containing GM-CSF) in 6-well plates.  On day 8 in culture the cells were counted 
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and replated at 0.5-1.0x106 cells per well.  Cells received either LPS (10ng/mL) + IFN-γ 
(20ng/mL) to stimulate the M1 condition, IL-4 (20ng/mL) to stimulate the M2 condition, or 
media alone to leave the cells undifferentiated (M0).  Cells were then harvested at the indicated 
time-points, generally 24 hours post-stimulation, using Hank’s Balanced Salt Solution (HBSS) 
on day 9 in culture and subsequently washed with PBS before cell lysis for RNA isolation. 
 
2.3 – RNA Isolation 
 To examine miRNA expression, cells were isolated using the miRvana isolation kit 
(Ambion) according to manufacturer specifications.  Samples were stored at -80 °C until 
analysis. 
 
2.4 – Reverse Transcription & Real-Time Polymerase Chain Reaction  
 To determine the relative expression of miRNA, Taqman Real Time PCR (RT-PCR) was 
used after an initial amplification using miR-155 and sno-202 primers to generate cDNA. 
Reverse transcription of 10 ng RNA was done using 100mM dNTPs, reverse transcriptase, 10X 
reverse transcription buffer, and RNAse inhibitor.  Reaction mixture was run in a thermal cycler 
at 16°C for 30minutes, at 42°C for 30 minutes, and at 85°C for 5 minutes.  PCR was performed 
using Taqman universal PCR mix and gene-specific miRNA primers.  Reaction mixture was run 
in RT-PCR machine denaturation step at 95°C for 10 minutes, followed by 40 cycles of 
denaturation at 95°C for 15 seconds and primer annealing/extension at 60°C for 60 seconds.  
miR-155 expression was set relative to the housekeeping gene sno202.   
 The relative gene expression of macrophage markers was determined using SYBR Green 
or Taqman quantitative RT-PCR.  cDNA was generated from 500 ng RNA per sample combined 
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with random hexamer primers (pN6) and 10mM dNTPs and then incubated at 65°C for 15 
minutes.  Resulting product was combined with first strand buffer, 0.1M DTT, and RNAse 
inhibitor and subsequently incubated at 25°C for 2 minutes.  Product was combined with 
Superscript II and the reaction mixture was run in thermalcycler at 25°C for 10 minutes, at 42°C 
for 50 minutes, and at 70 °C for 15 minutes.  Product was combined with 5uM forward and 
reverse primer of gene of interest and SybrGreen mix or with Taqman mix and Taqman probe 
before RT-PCR.  Expression of target genes was normalized to hypoxanthine guanidine 
phosphribosyltransferase (HPRT) as a loading control. RT-PCR data was analyzed using the 
comparative Ct (ΔΔCT) method [49] or the standard curve method [50] depending on whether 
the test gene and HPRT gene amplification efficiencies were comparable or not, respectively. 
 
2.5. Statistical analysis 
 Statistical significance was determined using analysis of variance (ANOVA) or unpaired 
t-test (two-tail, equal SD).  Statistical significance was determined to be p<0.05.  Analysis was 
completed using GraphPad Prism. 
 
III   Results 
3.1. Expression of miR-155 is selectively increased in M1 macrophages. 
 miRNA can regulate the expression of large numbers of genes at the post-transcriptional 
level. Therefore, specific miRNA expression signatures have been associated with various 
cellular lineages or phenotypes [50-54].  The expression of a selected group of miRNA 
reportedly associated with autoimmunity and/or inflammation was quantified in bone marrow 
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derived macrophages (BMDM) undergoing stimulation with lipopolysaccharide (LPS) and IFN-γ 
to differentiate into the M1 phenotype or with IL-4 to differentiate into the M2 phenotype 
(Fig. 2).  
 
Figure 2.   Experimental design.  Bone marrow-derived macrophages (BMDMs) were isolated from 
mice and left in media alone (M0), stimulated with LPS + IFNγ (M1), or stimulated with IL-4 (M2).  
RNA was isolated and then quantified via Real-Time PCR. 
 
The level of expression 24 hours post-activation was compared to that of M0 
macrophages kept in unstimulated but otherwise similar conditions (Fig. 3a).  The miRNA 
chosen for analysis were miR-27b, miR-29b, miR-155, miR-124 and miR-223. miR-27b has 
been found to be up-regulated in CD4+ T-cells isolated from patients with multiple sclerosis 
where it has been reported to be a regulator of the differentiation of CD4+ T-cells into Th1 and 
Th2 phenotypes which are analogous to the M1/M2 phenotypes in macrophages [55]. miR-29b is 18  
another miRNA that has been found to be up-regulated upon T cell activation as a negative 
feedback loop regulator of Th1 [54].  miR-124 has been reported to be associated with quiescent 
microglia and miR-223 with blood monocytes [57-58]. Finally, miR-155 was selected due to its  
association with a variety of inflammatory conditions and responsiveness to TLR stimulation 
[59-61].  miRNA expression was evaluated by Taqman based Real-Time PCR (RT-PCR) in 
samples taken 24 hours post-activation. The small RNA sno202 was used as housekeeping 
normalizing control gene.  We observed that, among the miRNAs tested, miR-155 was the most  
highly up-regulated (fold change (FC)± standard deviation (SD) =182 ±13, post-hoc ANOVA    
p< 0.0005) in M1 conditions while it was not up-regulated in alternatively activated (M2) 
macrophages (1.0±0.153) (Fig. 3a).  These data indicate that miR-155 is associated with M1 but 
not M2 activation. To better grasp the temporal pattern of miR-155 expression, we performed a 
time-course analysis of miR-155 expression. The relative expression of miR-155 was quantified 
at 6, 24, and 48 hours post-stimulation (Fig. 3b).  The expression of miR-155 in M1 
macrophages had already increased significantly (t test, p<0.0001) and reached its maximum 
observed expression by 6 hours post-stimulation. In contrast, M2 macrophages did not up-
regulate miR-155 at any of these time-points. The early and sustained expression of miR-155 led 
us to hypothesize that that miR-155 plays an important role in initiating the differentiation 
program of M1 macrophages that may be important in inflammatory responses to SCI.  
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Figure 3.  miR-155 is associated with the classically activated macrophage phenotype. 
Expression of miR-155 was determined by Taqman Real-Time PCR and expressed as mean relative 
expression (+ SEM) in (a)  macrophages stimulated in vitro for 24 hours in M0, M1, and M2 (n=3) 
conditions; expression relative to M0 condition;*** Post-hoc ANOVA p<0.005  (b) M1 and  M2 
macrophages activated in vitro over a 48 hour period; expression relative to 0 hour pre-stimulation 
time-point; **** unpaired t test p<0.0005 or (c) SCI tissue collected in vivo over a 42-day period; 
expression relative to uninjured spinal cord tissue; unpaired t-test, *p<0.05, **p<0.005   
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3.2. miR-155 is steadily up-regulated in the injured spinal cord tissue.   
To ascertain whether miR-155 expression in M1 BMDM is relevant to the inflammatory 
SCI process in vivo, we analyzed miR-155 expression in spinal cord tissue of mice (n=3-5/time-
point) that had received a thoracic contusion injury and compared it to that of uninjured spinal 
cord tissue. The relative expression of miR-155 in tissue isolated from SCI was quantified using 
RT- PCR (Fig. 3c). The data shows an increase in miR-155 at the site of injury in as early as 6 
hours post-injury.  The expression of miR-155 in tissue continued to steadily increase until 
reaching its observed maximum at 42 days post-injury (the last time point measured).  Since M1 
macrophages accumulate over time in the SCI tissue while M2 macrophages are lost the increase 
in miR-155 may, at least partially, reflect the accumulation of the miR-155 expressing M1 
population [19]. Overall, the observed miR-155 increase in SCI tissue supports the notion that  
miR-155 plays an important role in SCI inflammation and that miR-155 may be an important 
therapeutic target in SCI. 
 
3.3. Genetic loss of miR-155 significantly decreases M1 macrophage marker iNOS and TNF-α 
expression.  
 In order to determine the extent to which miR-155 contributes to the differentiation 
program of M1 macrophages, we determined the effect of genetic loss of miR-155 on the M1 
phenotype.  BMDMs were isolated from miR-155 WT (n=2) or KO (n=2) mice and stimulated 
into M0, M1 or M2 conditions (n=3 each) for 24 hours.  The expressions of two hallmark 
markers of M1 macrophages, iNOS and TNF-α, were analyzed by RT-PCR (Fig. 4). As 
expected, iNOS and TNF-α were expressed at a higher level in M1 than M2 WT macrophages.  
miR-155 deficiency abrogated iNOS expression in M1 macrophages as compared to WT (Fig. 
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4a, t test p<0.005).  Similarly, the relative expression of TNF-α was significantly reduced in 
miR-155 KO M1 macrophages (Fig. 4b, t test p<0.005).  Neither iNOS nor TNF-α was highly 
expressed in alternatively activated macrophages, highlighting the non-inflammatory phenotype 
of M2 macrophages in miR-155-sufficient or deficient macrophages. These data support the 
hypothesis that miR-155 is necessary for complete manifestation of the characteristic M1 
phenotype. However, we wondered whether its loss may additionally impair the M2 macrophage 
phenotype, which would not be beneficial to neuroregeneration.  
 
3.4. Genetic loss of miR-155 does not impair M2 macrophage marker Arg-1 and IL-13Rα 
expression. 
 To determine whether miR-155 loss altered M2 phenotype, we examined the expression 
of the characteristic M2 marker Arg-1 and of IL-13Rα by RT- PCR in WT (n=2) or miR-155 KO 
mice macrophages (n=2) exposed to M1 or M2 conditions for 24 hours. Arg-1 was highly 
expressed in M2 macrophages, as compared to the M1 condition, and was not affected by  
miR-155 deficiency (Fig. 5a, t test p>0.05). WT and miR-155 KO M1 macrophages had very 
low levels of Arg-1 expression compared with the M2 condition and showed a non-statistically 
significant increase in miR-155 KO M1 as compared to the WT M1 condition (Fig. 5a, p = 0.1).  
Similarly, miR-155 deficiency did not affect IL-13Rα in either M1 or M2 macrophages (Fig. 5b, 
p>0.05).  Overall, these data indicate that a classical M2 marker can still be properly expressed 
in the absence of miR-155.  
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 Figure 4.   Reduced M1 marker expression in miR-155 knock-out (KO) macrophages.  Inducible 
nitric oxide synthase (iNOS) (a) and Tumor Necrosis Factor-α (TNF-α) (b) expression was determined by 
Real-Time PCR in wild-type (WT, n=3) and miR-155 KO (n=3)bone marrow-derived macrophages in 
vitro activated in M1 or M2 conditions for 24 hours.  Gene expression is expressed as a percentage +/- 
SEM of the WT M1 condition. Unpaired t-test, **p<0.005 
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Figure 5.   Stable M2 marker expression in miR-155 KO macrophages.  Arginase-1 (Arg-1) (a) and 
IL-13Rα (b) expression was determined by Real-Time PCR in wild-type (WT, n=3) and miR-155 KO 
(n=3) bone marrow-derived macrophages in vitro activated in M1 or M2 conditions for 24 hours. Gene 
expression is expressed as a percentage +/- SEM of the WT M1 condition. Unpaired t-test: not significant. 
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3.5. In vitro pharmacologic inhibition of miR-155 reduces M1 macrophage polarization. 
 The significant decrease in expression of both iNOS and TNF-α in classically activated 
miR-155 KO macrophages prompted us to examine this pathway as a potential pharmacologic 
target.  Using an oligonucleotide-based inhibitor complementary to miR-155, we examined miR-
155 expression in WT BMDMs stimulated in M0, M1, or M2 conditions (n=3) as outlined in 
Materials and Methods (M&M).  As a control, we transfected BMDMs with a scrambled 
oligonucleotide inhibitor which lacks specificity for miR-155.  24 hours post-activation, we 
analyzed expression of iNOS and TNF-α by RT PCR.  The expression of iNOS in M1 
macrophages transfected with miR-155 inhibitor was significantly reduced by 85% as compared 
to the scrambled inhibitor (Figure 6a, p<0.05).  Similarly, TNF-α was significantly decreased in 
M1 macrophages transfected with miR-155 inhibitor as compared to WT (Figure 6b, p<0.05).  
The level of iNOS and TNF-α in undifferentiated macrophages did not exhibit a statistically 
significant difference in either case.  These results suggest that miR-155 is a promising 
pharmacologic target to limit the pro-inflammatory phenotype in macrophages. 
 
IV   Discussion 
 The poor recovery observed in SCI is the result of a combination of factors, including 
damage-induced auto-inflammatory mechanisms and inhibited neuronal recovery resulting from 
growth inhibitors at the site of injury.  Furthermore the formation of the glial scar around the site 
of injury presents a robust barrier which prevents the growth of neurons.  These detrimental 
functions have been linked (though not exclusively) to the pro-inflammatory M1 macrophage 
which infiltrates the site of injury.  Our findings suggest that the extent of polarization in 
macrophages can, at least in part, be regulated by miR-155.  
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Figure 6.  miR-155 inhibitor reduces M1 marker expression. Inducible nitric oxide synthase (iNOS) 
(a) and Tumor Necrosis Factor α (TNF-α) (b) expression was determined by Real-Time PCR in wild-type 
bone marrow-derived macrophages in vitro activated in M1 or M2 conditions for 24 hours and transfected 
with a scrambled (n=3) or a miR-155 oligonucleotide inhibitor (n=3). Gene expression is expressed as a 
percentage +/- SEM of the scrambled M1 condition. Unpaired t-test, *p<0.05 
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It has been previously shown that neurons exposed to media cultured with M1 
macrophages exhibit stunted neurite growth with more branching [19].  Conversely, neurons 
exposed to media cultured with M2 macrophages show longer neuron growth with less 
branching [19].  While both show neuron growth, the growth incurred by neurons exposed to M2 
media is more appropriate to recovery post-SCI.  Furthermore, the neurons exposed to M2 media 
experience greater survivability compared to neurons exposed to M1 media [19].  The neurons 
exposed to M1 media yield significantly reduced survivability versus both M2 media and control 
media.  It is therefore critical that the mechanism by which macrophage polarization is regulated 
is better understood and directed towards an increase in M2 macrophages and a reduction in M1 
macrophages. 
It has previously been reported that miR-155 may regulate signaling molecules involved 
in inflammatory pathways [59-60].  Until now, the role miR-155 plays in gene expression in 
opposed differentiated macrophages had not been previously described.  Here, we show that 
miR-155 is differentially expressed between classically activated and alternatively activated 
macrophages.   The expression of miR-155 increased rapidly and reached a plateau around six 
hours post-activation in M1 macrophages.  The expression of miR-155 in M2 macrophages 
remained comparatively low and did not demonstrate an increase.  In addition, the expression of 
miR-155 at the site of injury progressively increases up until six weeks post-injury.  
Furthermore, we show that by knocking out miR-155 in M1 macrophages, we can significantly 
reduce the expression of iNOS and TNF-α, two key genes involved in inflammation and 
secondary damage in SCI.  Furthermore, the pharmacologic inhibition of miR-155 using 
oligonucleotide inhibitors significantly reduced both iNOS and TNF-α expression. 
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The expression of the M2 markers Arg-1 and IL-13Ra seemed to remain stable in miR-
155 KO conditions.  These results have the important implication that miR-155 is not required 
for the expression of the M2 phenotype.  miR-155 inhibition resulted in observable increased 
Arg-1 in M1 macrophages at 24 hrs. Although this difference was not significant in the tested 
conditions, we cannot but wonder whether later time-points may allow an enhanced M2 
phenotype to manifest.  Since the mere reduction of the M1 phenotype during SCI would be 
expected to produce an improved environment for regeneration, these results are very promising. 
The mechanism by which miR-155 is up-regulated and how it then exerts its effect on 
inflammatory genes is not entirely understood. However, it seems conceivable that miR-155 up-
regulation is a result of TLR stimulation by PAMPs and DAMPs in the microenvironment. Once 
up-regulated, miR-155 may regulate inflammatory gene expression through various mechanisms.  
However, one possibility would be through regulation of suppressor of the cytokine signaling 
(SOCS) family proteins.  The SOCS family of proteins contains eight members (SOCS1-7 and 
CIS) which are important regulators of immune function and cytokine secretion; furthermore, 
SOCS1 mRNA can be targeted by miR-155 [61].  SOCS proteins are known to negatively 
regulate Janus kinase/signal transduction and transcription (JAK/STAT) signaling involved in 
the activation of pro-inflammatory transcription factors.  The protein SOCS1 is known to play a 
role in the regulation of inflammatory pathways and cytokines through the binding of the p65 
subunit of NF-κB and inducing its ubiquitin-dependent proteasomal degradation. miR-155 
therefore releases the negative regulation of NF-κB by SOCS1, resulting in the transcription of 
pro-inflammatory cytokines.  This model is the basis of current and future studies concerning the 
role of miR-155 in macrophage polarization and SCI recovery. 
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The ultimate goal of SCI research is to identify novel therapeutic strategies that can be 
used in human patients. The observed reduction in M1 markers and inflammatory gene 
expression associated with miR-155 inhibition or deficiency provides data to support targeting 
miR-155 as a therapeutic strategy. In devising therapeutic strategies, it is important to consider 
that macrophages play a critical role in the innate immune system and any alteration in the 
spectrum of M1/M2 phenotypes should be tightly regulated. For instance, prolonged exposure to 
cytokines and growth factors released by M2 macrophages has been associated with cancer and 
neoplasia [62-63].  Additionally prolonged deficiency in M1 macrophages creates vulnerability 
to bacterial infection, which remains a leading cause of mortality among patients enduring SCI.  
It is therefore important to be mindful that the modulation of macrophage phenotype should seek 
to create a more stable balance between M1 macrophages and M2 macrophages rather than to 
ablate either one.  In conclusion, while further investigation is required to determine its 
mechanism and its effect on neurons and functional recovery, this research illustrates a novel 
regulator of macrophage polarization and provides a foundational basis for the feasibility of 
miR-155 inhibition as method of SCI treatment.   
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